NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. cut its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 10.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,156,061 shares of the medical research company's stock after selling 733,084 shares during the quarter. Brown Advisory Inc. owned about 4.80% of NeoGenomics worth $101,452,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in shares of NeoGenomics by 2.0% in the 3rd quarter. Franklin Resources Inc. now owns 2,043,840 shares of the medical research company's stock valued at $28,225,000 after acquiring an additional 39,740 shares during the period. Versant Capital Management Inc increased its holdings in NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock valued at $30,000 after purchasing an additional 1,142 shares in the last quarter. Nordea Investment Management AB raised its position in NeoGenomics by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company's stock valued at $1,301,000 after purchasing an additional 2,125 shares during the period. Moody National Bank Trust Division lifted its stake in shares of NeoGenomics by 20.2% during the fourth quarter. Moody National Bank Trust Division now owns 73,226 shares of the medical research company's stock worth $1,207,000 after purchasing an additional 12,314 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management UK Ltd. lifted its stake in shares of NeoGenomics by 16.7% during the fourth quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 56,000 shares of the medical research company's stock worth $923,000 after purchasing an additional 8,000 shares in the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on NEO shares. Needham & Company LLC lowered their target price on NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Piper Sandler lowered their price objective on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Leerink Partners cut shares of NeoGenomics from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $25.00 to $9.00 in a research report on Wednesday, April 30th. The Goldman Sachs Group decreased their target price on shares of NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Finally, Leerink Partnrs lowered NeoGenomics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, NeoGenomics presently has an average rating of "Moderate Buy" and a consensus price target of $14.50.

NeoGenomics Stock Up 6.1 %

Shares of NASDAQ:NEO opened at $7.70 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The company's fifty day moving average is $9.40 and its two-hundred day moving average is $13.26. NeoGenomics, Inc. has a 1-year low of $6.08 and a 1-year high of $19.12. The stock has a market capitalization of $990.66 million, a price-to-earnings ratio of -12.42 and a beta of 1.41.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The company had revenue of $168.04 million during the quarter, compared to the consensus estimate of $171.38 million. During the same period last year, the business posted ($0.02) EPS. The company's revenue for the quarter was up 7.6% on a year-over-year basis. Equities analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.